Angiotensin-Converting Enzyme Inhibitors
-
Subject Areas on Research
-
1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).
-
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
-
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
-
A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research.
-
A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor.
-
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).
-
A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
-
ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement.
-
ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement.
-
ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients.
-
ACE inhibitors in hypertension: a US perspective.
-
ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice.
-
Acute coronary syndromes and diabetes mellitus.
-
Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.
-
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
-
Advanced heart failure: a call to action.
-
Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.
-
All that glitters is not gold.
-
Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine.
-
Amlodipine in chronic heart failure.
-
Angiotensin II and aldosterone in retinal vasculopathy and inflammation.
-
Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices.
-
Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation.
-
Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome.
-
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
-
Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease.
-
Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension.
-
Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele.
-
Angiotensin converting enzyme inhibitors and the cardiovascular system.
-
Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
-
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
-
Angiotensin-converting enzyme inhibition alters the inflammatory and fibrinolytic response to cardiopulmonary bypass in children.
-
Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis.
-
Angiotensin-converting enzyme inhibition: research advances and clinical implications.
-
Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal?
-
Angiotensin-converting enzyme inhibitor-induced angioedema associated with endotracheal intubation.
-
Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient.
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
-
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
-
Angiotensin-converting enzyme inhibitors: a new therapy for atrial fibrillation?
-
Antihypertensive drug exposure in premature infants from 1997 to 2013.
-
Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices.
-
Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function.
-
Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries.
-
Appropriateness of therapy with angiotensin-converting-enzyme inhibitors in elderly outpatients.
-
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
-
Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
-
Association Between HEDIS Performance and Primary Care Physician Age, Group Affiliation, Training, and Participation in ACA Exchanges.
-
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
-
Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome.
-
Association between performance measures and clinical outcomes for patients hospitalized with heart failure.
-
Association between systolic ejection time and outcomes in heart failure by ejection fraction.
-
Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF.
-
Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events: A Systematic Review and Meta-analysis.
-
Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.
-
Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study.
-
Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines.
-
Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
-
Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
-
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
-
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
-
Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
-
Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.
-
Can Angiotensin-converting enzyme inhibitors prevent dementia in elderly patients with diabetes mellitus?
-
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
-
Cardiac protection: evolving role of angiotensin receptor blockers.
-
Cardiac renin-angiotensin system. Molecular and functional aspects.
-
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study.
-
Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
-
Cell biology and genetics of angiotensin in cardiovascular disease.
-
Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
-
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
-
Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.
-
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
-
Circulating versus local renin-angiotensin system in cardiovascular homeostasis.
-
Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.
-
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Clinical implications for therapy: possible cardioprotective effects of ACE inhibition.
-
Clinical response to angiotensin-converting enzyme inhibition in cardiac failure.
-
Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.
-
Combining Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blocker for Clinical Decision-making Lacks Vision.
-
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
-
Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?
-
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
-
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
-
Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database.
-
Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
-
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
-
Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial.
-
Constructing a database of individual clinical trials for longitudinal analysis.
-
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
-
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.
-
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
-
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
-
Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure.
-
Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System.
-
Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors.
-
Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.
-
Current and novel pharmacologic approaches in advanced heart failure.
-
Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data.
-
Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition.
-
Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry.
-
Determining the most appropriate components for a composite clinical trial outcome.
-
Development and validation of a liquid chromatographic method for the determination of the related substances of ramipril in Altace capsules.
-
Diagnosis and management of renovascular hypertension.
-
Differential regulation of renin and Cox-2 expression in the renal cortex of C57Bl/6 mice.
-
Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts.
-
Diuretic resistance predicts mortality in patients with advanced heart failure.
-
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
-
Do the investigative sites that take part in a positive clinical trial translate that evidence into practice?
-
Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
-
Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
-
Dual renin-angiotensin system blockade in heart failure.
-
During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs.
-
Economics of treating heart failure.
-
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.
-
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
-
Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease.
-
Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure.
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
-
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
-
Effect of ramipril on the incidence of diabetes.
-
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
-
Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
-
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
-
Effects of converting enzyme inhibition with captopril on renal function in normal and ACTH treated sheep.
-
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
-
Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.
-
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
-
Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.
-
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
-
Effects on angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis.
-
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
-
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
-
Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
-
Electromechanical associations.
-
Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial.
-
Emerging role of the tissue renin-angiotensin systems in congestive heart failure.
-
Enalapril in infants with single ventricle: results of a multicenter randomized trial.
-
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators.
-
Evidence supporting secondary prevention strategies.
-
Evolution of the clinical management of hypertension. Emerging role of "specific" vasodilators as initial therapy.
-
FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.
-
Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II.
-
Fibroblast Growth Factor-23 Fans the Flames of Heart and Kidney Failure.
-
Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.
-
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
-
Focusing on inflammation in the treatment of atherosclerosis.
-
Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group.
-
Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative.
-
Growth Asymmetry, Head Circumference, and Neurodevelopmental Outcomes in Infants with Single Ventricles.
-
Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team.
-
Heart failure after myocardial infarction: A good heart is hard to find.
-
Heart failure medications prescribed at discharge for patients with left ventricular assist devices.
-
Heart failure survival score in patients with Chagas disease: correlation with functional variables.
-
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
-
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts.
-
Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
-
Hypertension Update: Resistant Hypertension.
-
Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points.
-
Hypertension with acute coronary syndrome and heart failure.
-
Hypertension.
-
Hypertensive heart failure: patient characteristics, treatment, and outcomes.
-
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.
-
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure.
-
Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis.
-
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
-
Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes.
-
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.
-
Impact of estimated GFR reporting on patients, clinicians, and health-care systems: a systematic review.
-
Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries.
-
Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST).
-
Implications of local angiotensin production in cardiovascular physiology and pharmacology.
-
Improved outcome in heart failure.
-
Improved outcomes in peripartum cardiomyopathy with contemporary.
-
Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease.
-
Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis.
-
Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF).
-
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
-
Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.
-
Initial therapy of hypertension.
-
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
-
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
-
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
-
Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly.
-
Insights into the contemporary epidemiology and outpatient management of congestive heart failure.
-
Intensity and focus of heart failure disease management after hospital discharge.
-
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
-
Interventions for Diabetic Retinopathy in Type 1 Diabetes: Systematic Review and Meta-Analysis.
-
Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis.
-
Invited commentary.
-
Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic?
-
Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications.
-
Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
-
Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?
-
Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?
-
Large conduit arteries in hypertension: role of the vascular renin-angiotensin system.
-
Left ventricular dysfunction: causes, natural history, and hopes for reversal.
-
Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study.
-
Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema.
-
Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart.
-
Long-term adherence with cardiovascular drug regimens.
-
Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction.
-
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
-
Losartan in post-transplant erythrocytosis.
-
Lovastatin and coadministered antihypertensive/cardiovascular agents.
-
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
-
Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation.
-
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
-
Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients.
-
Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
-
Management of acute decompensated heart failure.
-
Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.
-
Mechanism of protective effects of ACE inhibition on coronary artery disease.
-
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.
-
Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease.
-
Medical Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
-
Medical advances in the treatment of congestive heart failure.
-
Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF.
-
Medication performance measures and mortality following acute coronary syndromes.
-
Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians.
-
Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.
-
Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia.
-
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
-
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.
-
Natriuretic peptides and primary prevention: the new world?
-
Nebivolol in older adults with heart failure: reduced rates for seniors?
-
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
-
Novel peptide inhibitors of angiotensin-converting enzyme 2.
-
Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry.
-
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
-
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
-
Outpatient management of heart failure in the United States, 2006-2008.
-
Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial.
-
Overview of current noninodilator therapies for acute heart failure syndromes.
-
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
-
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
-
Patient Perceptions and Familiarity With Medical Therapy for Heart Failure.
-
Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
-
Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality.
-
Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
-
Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.
-
Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.
-
Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system.
-
Pharmacotherapy for human immunodeficiency virus-associated nephropathy.
-
Phosphate REINs in the renoprotective benefit of ACE inhibition.
-
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.
-
Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?
-
Post-Myocardial Infarction Heart Failure.
-
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.
-
Postcoronary thrombolysis management.
-
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
-
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial.
-
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality.
-
Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation.
-
Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure.
-
Poverty, process of care, and outcome in acute coronary syndromes.
-
Pragmatic and mechanistic trials.
-
Precardiac surgery angiotensin-converting enzymes and mineralocorticoid blockers do not trump atrial fibrillation but possibly acute kidney injury: the value of a negative randomized study.
-
Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
-
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
-
Predictors of survival after cardiac arrest in outpatient hemodialysis clinics.
-
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
-
Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor.
-
Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery.
-
Prescribing BiDil: is it black and white?
-
Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.
-
Prevention and health services delivery.
-
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
-
Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.
-
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
-
Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction.
-
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
-
Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses.
-
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
-
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.
-
Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition.
-
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.
-
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
-
Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF.
-
Protease inhibitors are associated with a slowed progression of HIV-related renal diseases.
-
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
-
Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program.
-
Quality of medical care and excess mortality in older patients with mental disorders.
-
Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America.
-
Quinapril--a new angiotensin-converting enzyme inhibitor: an overview.
-
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
-
Racial differences are seen in blood pressure response to fosinopril in hypertensive children.
-
Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.
-
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.
-
Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.
-
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
-
Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
-
Rationale and design of a trial of angiotensin-converting enzyme inhibition in infants with single ventricle.
-
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
-
Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells.
-
Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction.
-
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
-
Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II.
-
Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study.
-
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
-
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators.
-
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
-
Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.
-
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
-
Reliability of drug utilization evaluation as an assessment of medication appropriateness.
-
Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
-
Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors.
-
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.
-
Renal vascular reactivity in mice: AngII-induced vasoconstriction in AT1A receptor null mice.
-
Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
-
Renin-angiotensin system and renal circulation in clinical congestive heart failure.
-
Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?
-
Renovascular hypertension in blacks.
-
Reperfusion for acute myocardial infarction: is the future in plastics?
-
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
-
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
-
Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".
-
Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
-
Rhythm control versus rate control for atrial fibrillation and heart failure.
-
Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit.
-
Screening for proteinuria in US adults: a cost-effectiveness analysis.
-
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
-
Secondary mitral and tricuspid regurgitation accompanying left ventricular systolic dysfunction: is it important, and how is it treated?
-
Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure.
-
Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials).
-
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
-
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.
-
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.
-
Short- and long-term determinants of cardiovascular function and therapy: contributions of circulating and tissue renin-angiotensin systems.
-
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
-
Species variability in angiotensin receptor expression by cultured cardiac fibroblasts and the infarcted heart.
-
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.
-
Stimulus-response curve of the renal baroreceptor: effect of converting enzyme inhibition and changes in salt intake.
-
Strategies for preventing diabetic nephropathy.
-
Strategies to attenuate pathological remodeling in heart failure.
-
Success stories: how hospitals are improving care.
-
Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.
-
Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
-
Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
-
Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria.
-
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.
-
Temporal trends in medical therapies for ST- and non-ST elevation myocardial infarction: (from the Atherosclerosis Risk in Communities [ARIC] Surveillance Study).
-
The ABCs of managing systolic heart failure: Past, present, and future.
-
The State of Percutaneous Intervention in Stable Coronary Artery Disease.
-
The benefit of implementing a heart failure disease management program.
-
The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
-
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.
-
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
-
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.
-
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
-
The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic.
-
The past, present and future of renin-angiotensin aldosterone system inhibition.
-
The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
-
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
-
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.
-
The renin-angiotensin system and diabetic nephropathy.
-
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
-
The role of heart failure pharmacotherapy after left ventricular assist device support.
-
The role of systemic hypertension in the progression of nondiabetic renal disease.
-
Therapies to prevent heart failure post-myocardial infarction.
-
Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors.
-
Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials.
-
Tissue renin-angiotensin system: physiologic and pharmacologic implications. Introduction.
-
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
-
Translating clinical trials into clinical practice: a survey assessing the potential impact of the Pediatric Heart Network Infant Single Ventricle Trial.
-
Treatment and risk in heart failure: gaps in evidence or quality?
-
Treatment gaps in the pharmacologic management of heart failure.
-
Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.
-
Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program.
-
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
-
Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
-
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
-
Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.
-
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.
-
Use of combination antihypertensive therapy initiation in older Americans without prevalent cardiovascular disease.
-
Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators.
-
Use of guideline-recommended therapies for heart failure in the Medicare population.
-
Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program.
-
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
-
Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
-
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
-
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
-
Valsartan, captopril, or both in myocardial infarction.
-
Valvular heart disease.
-
Vascular renin-angiotensin system and vascular protection.
-
Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors.
-
Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database).
-
What can knockout mice contribute to an understanding of hypertension?
-
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
-
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
-
Zofenopril after anterior myocardial infarction.
-
[Anti-hypertensive treatment in metabolic syndrome--focus on ARB or ACE inhibitor].
-
Keywords of People
-
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Barker, Piers Christopher Andrew,
Professor of Pediatrics,
Pediatrics, Cardiology
-
Granger, Christopher Bull,
Professor of Medicine,
School of Nursing
-
Middleton, John Paul,
Professor of Medicine,
Medicine, Nephrology
-
O'Connor, Christopher Michael,
Richard Sean Stack, M.D. Distinguished Professor,
Medicine, Clinical Pharmacology
-
Patel, Uptal Dinesh,
Adjunct Professor in the Department of Medicine,
Medicine, Nephrology
-
Yancy Jr., William Samuel,
Associate Professor of Medicine,
Medicine, General Internal Medicine